Key Insights - The report highlights significant capital expenditure increases among the four major CSP manufacturers, driven by demand that is pushing up power semiconductor prices, indicating a robust recovery in the electronic sector [6][7] - The semiconductor industry is expected to reach a historic high in sales in 2025, with a projected increase in demand for computing power due to AI infrastructure investments [8] - The excavator market saw a substantial increase in both domestic and export sales in January 2026, indicating strong demand recovery in the machinery sector [13][14] - The small nucleic acid sector is gaining traction, with notable collaborations and sales growth, reflecting the increasing value of this market segment in the pharmaceutical industry [18][19] Group 1: Electronic Industry - The electronic sector is experiencing a recovery, with AI infrastructure investments leading to a surge in capital expenditures among major CSPs, expected to reach $670 billion in 2026, a 60% increase year-on-year [7] - The global semiconductor sales reached $791.7 billion in 2025, with a projected increase to over $1 trillion in 2026, driven by demand from AI and IoT technologies [8] - The price increase trend in semiconductors is spreading from memory chips to power, analog, and MCU chips, indicating a comprehensive price cycle in the semiconductor industry [8] Group 2: Machinery Industry - In January 2026, excavator sales increased by 49.5% year-on-year, with domestic sales up 61.4% and exports up 40.5%, reflecting strong demand recovery [13][14] - The loader market also saw significant growth, with sales increasing by 48.5% year-on-year, driven by major domestic projects and a growing overseas market [15] - The overall machinery industry is expected to continue its recovery, supported by government policies and infrastructure projects [14][15] Group 3: Pharmaceutical Industry - The small nucleic acid sector is highlighted for its potential, with a recent collaboration between Saint Gene and Gene Tech valued at up to $1.7 billion, showcasing the sector's growth and international recognition [19][20] - The pharmaceutical sector overall saw a slight increase of 0.14% in the last week, with certain sub-sectors like traditional Chinese medicine and medical services performing particularly well [18] - Investment opportunities are identified in biotech firms with core delivery technologies and those focusing on chronic disease areas, indicating a shift towards more sustainable growth in the pharmaceutical market [20]

截至2026年2月10日 13:20，中证医药及医疗器械创新指数(931484)上涨0.57%，成分股惠泰医疗上涨 4.86%，海思科上涨3.61%，康龙化成上涨2.55%，药明康德上涨2.31%，恩华药业上涨1.89%。医疗创新 ETF(516820)上涨0.55%，最新价报0.37元。 消息面上，2月9日，1-8批国家集采药品新一轮接续采购开标产生拟中选结果。本次接续采购涉及1-8批 国家集采的316种常用药品，覆盖抗感染、抗肿瘤、降血糖、降血压、降血脂、神经系统、呼吸系统、 消化系统等26个治疗领域。全国5.1万家医药机构参加报量，共1091家国内外企业的4623个产品参与投 标，1020家企业的4163个产品获得拟中选资格。 东海证券指出，小核酸赛道的高景气度持续延续，从罕见病向慢病领域加速渗透，市场规模持续扩容； 跨国药企布局意愿提升，国内本土企业技术获国际认可，出海路径清晰，供应链优势凸显，板块投资价 值持续提升。后续投资建议聚焦三大核心主线：一是具备核心递送技术、拥有国际合作潜力的新锐 biotech；二是布局慢病领域（心血管、代谢等）、管线进度领先、可复制Leqvio商业化路径的行业龙 头；三 ...

Investment Rating - The industry investment rating for the pharmaceutical and biotechnology sector is "Hold" [2]. Core Insights - The report highlights significant advancements in the field of metabolic disorders, particularly focusing on the PCSK9 target and small nucleic acid therapies, driven by the increasing prevalence of dyslipidemia in China, which now affects over 400 million people [5][7]. - Novartis' innovative cholesterol-lowering drug, Leqvio (inclisiran), has received approval for a new indication in China, aimed at treating adult patients with primary hypercholesterolemia or mixed dyslipidemia, enhancing treatment adherence and long-term management of LDL-C levels [5][6]. Summary by Sections Industry Overview - The report discusses the acceleration of resource integration and the rapid development of brain-computer interface technologies, indicating a shift towards innovative treatment paradigms in the medical field [4]. Market Dynamics - The number of patients with dyslipidemia in China has significantly increased, with a notable rise in cases of hypercholesterolemia, particularly among younger populations [6]. - The report notes that the global clinical development pipeline for PCSK9-targeted therapies includes 55 projects, with a focus on monoclonal antibodies and emerging small nucleic acid drugs [6]. Investment Recommendations - The report suggests investors pay attention to companies such as Heng Rui Medicine, Innovent Biologics, and East China Pharmaceutical, which are positioned to benefit from advancements in the metabolic disorder treatment landscape [7].

华源证券研报指出，福元医药仿制药基本盘稳健，小核酸打开成长天花板。公司在稳固仿制药基本盘的 同时，近年来加速布局小核酸创新药，有望打开中长期成长空间。充裕的资金储备与稳健的经营性现金 流，使公司具备以自有资金推进转型创新药的能力。展望未来，1-8批集采品种全国统一接续采购即将 落地，已中标品种若接续有望延续报量、未中标品种或存在边际修复空间；叠加第十一批集采新中标品 种有望贡献增量，仿制药主业有望持续为公司贡献稳定的现金流。公司坚持"仿创结合"的研发战略，前 瞻性切入小核酸赛道，研发投入持续加码，研发费用从2021年的1.8亿元提升至2024年的4.17亿元。考虑 到公司仿制药基本盘稳健，小核酸创新药布局具备长期成长弹性，以及账面现金充沛，首次覆盖，给 予"买入"评级。 ...

Core Viewpoint - The first domestic pharmaceutical merger of the year occurred when China National Pharmaceutical Group announced the acquisition of Hegia Biotech for 1.2 billion RMB, marking a strategic move to strengthen its position in the small RNA drug sector and expand into the global chronic disease treatment market [1][2]. Group 1: Acquisition Details - The acquisition price for Hegia Biotech is set at 1.2 billion RMB, and upon completion, Hegia will become a wholly-owned subsidiary of China National Pharmaceutical Group, retaining its founding team [2]. - Hegia Biotech has developed a unique liver-targeted delivery platform for siRNA, which is the only clinically validated system capable of long-term administration with a single injection per year [3]. - Hegia has a robust pipeline with four innovative drugs in clinical stages and over 20 candidates in preclinical development, covering various therapeutic areas [2][3]. Group 2: Strategic Implications - The acquisition is seen as a critical step in positioning China National Pharmaceutical Group for the next generation of drug paradigms, aiming for deep synergy with its existing clinical development and commercial expansion capabilities [3]. - The company has previously invested in the small RNA sector, indicating a systematic approach to securing next-generation drug technologies [3]. - The strategic focus on oncology and chronic diseases aligns with the anticipated market opportunities, as the company aims to create substantial value for shareholders through these acquisitions [9]. Group 3: Leadership and Historical Context - The acquisition highlights the leadership of Xie Qirun, a young executive from the fourth generation of the Xie family, who has been pivotal in steering the company towards innovation and strategic acquisitions [5][6]. - Under her leadership, the company has transitioned from having only two innovative products a decade ago to 21, with a significant increase in the revenue share from innovative drugs [9]. - The historical context of the Xie family’s involvement in the pharmaceutical industry dates back over a century, with a focus on biopharmaceuticals since the early 1990s [6][7]. Group 4: Industry Trends - The trend of mergers and acquisitions in the pharmaceutical industry is gaining momentum in China, mirroring global practices where large pharmaceutical companies acquire biotech firms to enhance their innovation capabilities [11][12]. - The Chinese pharmaceutical market is expected to see a surge in innovation-driven deals, with projections indicating a significant increase in the value of drug development and licensing agreements [12]. - The strategic direction of China National Pharmaceutical Group reflects a broader industry shift towards global competitiveness and the need for innovative therapies to meet growing healthcare demands [13].

Company Overview - The company announced a 100% acquisition of Hejia Bio for a consideration of 1.2 billion yuan, which is adjustable [1] - The payment structure includes a mix of cash and equity, with 50% cash payment to founding shareholders on the closing date and the remaining 50% to be unlocked over 24 to 36 months [1] Industry Insights - Hejia Bio specializes in siRNA innovative drugs, focusing on three major chronic disease areas: weight management, cardiovascular, and neurological systems [1] - The core platform, MVIP, is the world's first clinically validated liver-targeted delivery platform capable of achieving long-lasting effects with annual injections [1] - The dual delivery technology addresses the industry challenge of achieving combined efficacy, while the neural targeting delivery platform aims for effective central and peripheral nervous system treatments [1] Strategic Implications - The acquisition is expected to enhance the company's capabilities in chronic disease management, addressing existing limitations in efficacy, safety, and patient compliance in current therapies [2] - The collaboration is anticipated to accelerate the clinical development and commercialization of Hejia Bio's products, leveraging the company's established R&D and sales channels [2] Financial Projections - The adjusted net profit forecasts for 2025 and 2026 remain at 4.47 billion yuan and 4.92 billion yuan, respectively, with an introduction of a 2027 adjusted net profit of 5.42 billion yuan [2] - The current stock price corresponds to adjusted P/E ratios of 23.8 and 21.0 for 2026 and 2027, respectively, with a target price of 8.90 HKD, indicating a potential upside of 28.8% [2]

Core Viewpoint - China National Pharmaceutical Group announced the acquisition of domestic siRNA innovative drug company Hejia Bio for a total price of 1.2 billion RMB, marking a significant move in the small nucleic acid sector following its investment in Saintin Bio [1] Group 1: Company Overview - China National Pharmaceutical Group's stock rose over 4% in early trading, currently at 7.12 HKD with a trading volume of 134 million HKD [1] - Hejia Bio is a pioneering biopharmaceutical company focused on the research and development of small interfering RNA (siRNA) innovative drugs [1] Group 2: Strategic Importance - The acquisition of Hejia Bio represents a key strategic investment in the small nucleic acid space, following the previous investment in Saintin Bio [1] - Hejia Bio has developed an integrated drug development system from target discovery to proof of concept (POC), focusing on three major chronic disease areas: weight loss metabolism, cardiovascular and cerebrovascular, and nervous system [1] Group 3: Asset Portfolio - Hejia Bio possesses four clinical-stage assets and over ten preclinical assets, all of which have first-in-class and best-in-class potential [1]

Group 1 - The core point of the article is that China National Pharmaceutical Group announced a full acquisition of domestic siRNA innovative drug company Hejia Bio for a total price of 1.2 billion RMB, marking a significant move in the small nucleic acid sector [1] - The acquisition follows the company's previous investment in Saintin Bio, indicating a strategic focus on the small nucleic acid drug development space [1] - Hejia Bio is recognized as a pioneer in the research and development of small interfering RNA (siRNA) innovative drugs, with a comprehensive drug development system from target discovery to proof of concept (POC) [1] Group 2 - Hejia Bio is focused on three major chronic disease areas: weight loss metabolism, cardiovascular and cerebrovascular diseases, and neurological disorders [1] - The company possesses four clinical-stage assets and over ten preclinical assets, all of which have first-in-class and best-in-class potential [1]

Core Viewpoint - China Biopharmaceutical (01177.HK) announced a strategic acquisition of Hegia for a total price of 1.2 billion yuan, aiming to enhance its innovation layout and clinical advancement in the chronic disease sector, particularly in the field of small interfering RNA (siRNA) therapies [1][2]. Group 1: Acquisition Details - The acquisition price of Hegia is set at 1.2 billion yuan, which is subject to adjustment [1]. - Hegia specializes in the development of siRNA innovative drugs and has established an integrated drug development system from target discovery to proof of concept (POC) [1][2]. Group 2: Hegia's Capabilities - Hegia has developed six liver-targeted and extrahepatic delivery platforms, including MVIP, which is the world's first clinically validated platform allowing for "once-a-year" long-acting administration [2]. - The company has four innovative drugs currently in clinical stages, including Kylo-11, which is the first siRNA for treating hyperlipoproteinemia (a) with a once-a-year dosing schedule, currently in Phase II clinical trials [3]. Group 3: Strategic Importance - The acquisition is expected to leverage Hegia's strengths in sequence design, delivery systems, and chemical modifications, complementing China Biopharmaceutical's experience in molecular forms, patent layout, and clinical translation [2]. - The small nucleic acid sector has become one of the most promising areas in the biopharmaceutical industry, with a total disclosed transaction value of approximately 35 billion USD since 2025, reflecting a year-on-year growth of over 40% [3].

Group 1 - China Biologic Products announced the acquisition of 100% equity in Hejiya Biotech for 1.2 billion RMB, enhancing its position in the small RNA (siRNA) sector [1] - This acquisition follows a previous purchase of Lixin Pharmaceutical for approximately 3.5 billion RMB in July 2025, indicating a strategic focus on expanding its small RNA portfolio [1] - The stock price of China Biologic Products closed at 6.91 HKD per share, with a market capitalization of 129.6 billion RMB as of January 13 [1] Group 2 - Hejiya Biotech, established in 2018, specializes in innovative siRNA products with advantages in long-lasting effects and low dosages, boasting six delivery platforms and four innovative drugs in clinical stages [2] - Hejiya's Kylo-11, targeting LPA, is the first siRNA product to achieve "one injection per year" in clinical trials, marking a significant advancement in the treatment of hyperlipidemia [2] - The company has over 20 projects in preclinical stages, covering high-value areas such as cardiovascular, metabolic, and neurological diseases [2] Group 3 - The acquisition allows China Biologic Products to complete its innovative drug layout in the cardiovascular field and significantly expand into major chronic disease areas [3] - The chairman of China Biologic Products emphasized that Hejiya's differentiated delivery technology platform will enhance the company's core competitiveness in the small RNA sector [3] - Industry experts believe this acquisition represents a strategic alignment of technical capabilities and commercialization strengths, potentially accelerating the market introduction of Hejiya's siRNA drug pipeline [3]